SEC Comment Letter for Biodexa Pharmaceuticals Plc (BDRX) (CIK 0001643918) (BDRX) — Aug 20, 2025

Biodexa Pharmaceuticals Plc (BDRX) (CIK 0001643918)
Date: Aug. 20, 2025 · CIK: 0001643918 · Accession: 0000000000-25-008869

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-37652

Date

August 20, 2025

Author

Finance

Form

UPLOAD

Company

Biodexa Pharmaceuticals Plc (BDRX) (CIK 0001643918)

Letter

Re: Biodexa Pharmaceuticals plc Form 20-F for Fiscal Year Ended December 31, 2024 File No. 001-37652 Dear Stephen Stamp:

August 20, 2025

Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals plc 1 Caspian Point Caspian Way Cardiff, CF10 4DQ, United Kingdom

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,
Division of Corporation
Finance
Office of Life Sciences

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 20, 2025

Stephen Stamp
Chief Executive Officer
Biodexa Pharmaceuticals plc
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ, United Kingdom

 Re: Biodexa Pharmaceuticals plc
 Form 20-F for Fiscal Year Ended December 31, 2024
 File No. 001-37652
Dear Stephen Stamp:

 We have completed our review of your filing. We remind you that the
company and
its management are responsible for the accuracy and adequacy of their
disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

 Sincerely,

 Division of Corporation
Finance
 Office of Life Sciences
</TEXT>
</DOCUMENT>

SecProbe.io